Savara Inc.

Savara Inc.

SVRA·NASDAQ

$5.32

+1.4%
HealthcareBiotechnology

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

At a Glance

Live Snapshot
Market Cap$1.09B
EPS-0.5300
P/E Ratio-10.05
Earnings Date08/06/2026

svra

Cash at Beginning of Period

Last Annual Value

15.13M

3-Year CAGR

-24%

5-Year CAGR

-21%

10-Year CAGR

-8%

Savara Inc.

Savara Inc. Competitors Analysis of Cash at Beginning of Period

SVRA · NASDAQ
CompanyCash at Beginning of Period
CAGR 3Y
CAGR 5Y
CAGR 10Y
SVRA logo
Savara Inc.
NASDAQ:SVRA
15.13M
-33.8%-7.9%-1.0% 
224.46M
63.0%-7.2%30.7%
80.88M
12.2%51.0%14.3%
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
70.40M
-22.4%47.9%29.6%
489.71M
390.2%N/AN/A
72.10M
4.1%18.7%N/A
92.97M
-28.2%43.1%N/A
99.85M
1.5%17.3%18.0%
PROK logo
ProKidney Corp.
NASDAQ:PROK
99.12M
-41.3%85.0%N/A
Savara Inc.

Savara Inc. Fair Value Envelope

SVRA · NASDAQ

Our analysis suggests that SVRA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.3249, this represents a potential HIDDEN relative to our calculated worth for Savara Inc..

Intrinsic Value
Current Price: $5.3249